stockrow
Saturday 7 November 2026
Export AVTX’s income statement to Excel — free account
Avalo Therapeutics, Inc.
AVTX Healthcare Biotechnology
Avalo Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $59,000.00, down 86.6% from fiscal 2024.
- Revenue
- −70.1%
- EPS
- +56.8%
- Free cash flow
- +75.7%
Quarter to June 2026, against a year earlier
6.95
0.32
+4.83%
Follow AVTX
Alert me
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (36.27%) | (88.76%) | (72.43%) | (177.05%) |
+8 more TTM periods Free account |
|
| (32.50%) | (71.09%) | (58.58%) | (89.20%) | ||
ROIC |
(118.21%) | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(25.92%) | (109.20%) | (84.33%) | (93.69%) | |
Average Days of Receivables |
— | — | — | — | |
Free Cash Flow per Share |
(1.57) | (2.97) | (3.84) | (3.73) | |
Free Cash Flow |
(68.29) | (59.69) | (51.46) | (52.26) | |
| Other line items | |||||
Cash ROIC |
(8.04%) | (39.67%) | (28.36%) | (25.71%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Operating CF/Net income |
0.68 | 0.70 | 0.66 | 0.52 | |
Depreciation/Fixed assets |
0.38 | 0.60 | 0.75 | 0.73 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(1.57) | (2.97) | (3.84) | (3.73) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates · fundamentals updated 26 Oct 2026